Immunotherapy of non‑small cell lung cancer with anti‑PD‑L1 antibodies

04/2017

Prof. MUDr. Vítězslav Kolek, DrSc.

Klinika plicních nemocí a tuberkulózy LF UP a FN, Olomouc

SUMMARY

An immuno-therapy directed at the inhibition of PD-L1 (programmed death-ligand 1) protein ligand in patients with non-small cell lung cancer in the second or third line of treatment is reported, according to the results of the POPLAR and OAK studies. The atezolizumab treatment product showed an improvement in survival compared to docetaxel in all subgroups of patients with the exception of tumors with epidermal growth factor receptor and anaplastic lymphoma kinase positivity. Efficacy was greatest in tumors with high expression of PD-L1 and large lymphocytic infiltration of the tumor but was found even in low or inconclusive expression. The drug was very well tolerated and is another hope for patients with metastatic and locally advanced non-small cell lung carcinoma.

KEY WORDS

non-small cell lung cancer, immunotherapy, immune checkpoint inhibitors, anti-PD-LI antibodies